FierceBiotech FierceBiotech IT FiercePharma FierceMedicalDevices
FierceBiotech Research FierceVaccines FiercePharma Manufacturing FierceDrugDelivery

Free Newsletter

About | View Sample | Privacy
Related Topics >> celiac disease | ImmusanT | Microtest

Microtest to manufacture ImmusanT's celiac vaccine

Free Newsletter

FierceVaccines is a weekly update on the vaccine industry, with a special focus on the innovations revolutionizing the development and production of vaccines. Join thousands of lab research professionals who get FierceVaccines via weekly email. Sign up today!



Tools

Microtest Laboratories will manufacture Nexvax2 for a mid-stage trial of ImmusanT's vaccine as a treatment for celiac disease. ImmunsanT secured $20 million in venture captial funding from Vatera Healthcare Partners in December to advance clinical development of the vaccine. Article


SHARE
WITH:
Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FierceVaccines Email Newsletter:

More stories about celiac disease   ImmusanT   Microtest